MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Tonix Pharmaceuticals Holding Corp. Company Profile (NASDAQ:TNXP)

Consensus Ratings for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (436.59% upside)

Analysts' Ratings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Cantor FitzgeraldUpgradeSpeculative Buy -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Roth CapitalReiterated RatingBuy$7.50 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.58)($0.58)($0.58)
Q2 20163($0.63)($0.49)($0.56)
Q3 20162($0.49)($0.31)($0.40)
Q4 20162($0.45)($0.21)($0.33)
(Data provided by Zacks Investment Research)
Dividend History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
DateHeadline
06/25/16 10:30 AMShare Volatility Check for: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Press Telegraph
06/25/16 10:30 AMTonix Pharmaceuticals Holding Corp. (TNXP) Current Analyst Ratings - Fiscal Standard
06/23/16 07:36 PMWhat The Future Holds For Tonix - Seeking Alpha
06/23/16 09:25 AMChief Executive Officer of Tonix Pharmaceuticals Holding C (NASDAQ:TNXP), Lederman Seth, buys 20,000 shares worth $41,500
06/22/16 07:45 AMCan You Catch These 6 Stocks Under $10 on Their Way Up? -
06/22/16 06:55 AMKingsway Financial Services Inc. (USA) (KFS) and Two Pharmaceutical Companies Register Insider Buying -
06/21/16 06:21 PMTONIX PHARMACEUTICALS HOLDING CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
06/21/16 06:21 PMDirector of Tonix Pharmaceuticals Holding C (NASDAQ:TNXP), Rhodes John B, buys 25,000 shares worth $50,000
06/20/16 06:24 PMStrong Buy Calls Count For Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) At 3 - Investor Newswire
06/17/16 07:00 AMTonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference - [GlobeNewswire] - NEW YORK, June 17, 2016-- Tonix Pharmaceuticals Holding Corp., which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder, announced today that Seth Lederman, M.D., ...
06/16/16 10:59 AMTONIX PHARMACEUTICALS HOLDING CORP. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
06/16/16 10:59 AMTonix Pharma's stock plummets after stock offering prices at deep discount
06/16/16 10:59 AMTonix Pharmaceuticals Prices Secondary Offering
06/13/16 02:40 PMTNXP: A Closer Look at Data from the AtEase Trial of TNX-102 SL in Military-Related PTSD… -
06/12/16 06:55 PMTrend Of Rating Given To Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Investor Newswire
06/10/16 09:56 AMCan Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Meet Analysts Expectations? - Stocks Daily
06/09/16 07:23 PMTonix Pharmaceuticals (TNXP) Announces Presentation of Encouraging TNX-102 SL Phase 2b Data in Fibromyalgia
06/09/16 09:56 AMTonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
06/07/16 07:07 PMTONIX PHARMACEUTICALS HOLDING CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
06/03/16 06:00 AMTonix Pharmaceuticals to Present at the 2016 BIO International Convention - [GlobeNewswire] - NEW YORK, June 03, 2016-- Tonix Pharmaceuticals Holding Corp., which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder, announced today that Seth Lederman, M.D., ...
06/03/16 05:05 AMTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye -
06/02/16 07:22 PMTonix Pharmaceuticals Holding Corp. (TNXP) – Research Analysts' Weekly Ratings Updates - Let Me Know About This - Business Finance NewsTonix Pharmaceuticals Holding Corp. (TNXP) – Research Analysts' Weekly Ratings UpdatesLet Me Know About ThisTonix Pharmaceuticals Holding Corp. logo Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) recently received a number of ratings updates from brokerages and research firms: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up 4.51% ...Buy, Sell Or Hold Rating For Tonix Pharmaceuticals Holding Corp. (TNXP)?Share Trading NewsTop Stock in Session: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)The PostBroker Changes For Tonix Pharmaceuticals Holding Corp. (TNXP)Risers & FallersFranklin Independent -HNN -Benchmark Monitorall 12 news articles »
06/02/16 10:05 AMStock Review and Earnings Check on Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - HNN - Stock Review and Earnings Check on Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to report quarterly EPS of $-0.57. The company's next earnings report is expected to ...and more »
06/01/16 09:51 AMCoca-Cola Enterprises, Inc. (NYSE:CCE) Plummeted -24.71%: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP ... - KC Register - Coca-Cola Enterprises, Inc. (NYSE:CCE) Plummeted -24.71%: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP ...KC RegisterTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded 643170 shares and its share price advanced 6.55% to close at $2.44. Company has 3.00% insider ownership. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) quarterly performance is ...
05/31/16 09:55 AMTonix Pharmaceuticals (TNXP) Announces Presentation of TNX-102 SL Phase 2 Data in PTSD; Four SAEs Noted - StreetInsider.com - Tonix Pharmaceuticals (TNXP) Announces Presentation of TNX-102 SL Phase 2 Data in PTSD; Four SAEs NotedStreetInsider.comTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the presentation of positive results from its Phase 2 dose-finding clinical study (AtEase Study) of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related ...Tonix Pharmaceuticals Shares Surge 15% Pre-Bell on Positive PTSD Treatment Study Results (NASDAQ:TNXP)Sonoran Weekly Reviewall 2 news articles »
05/31/16 09:55 AMGlycoMimetics, Inc. (NASDAQ:GLYC) rose 2.79%: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP ... - KC Register - GlycoMimetics, Inc. (NASDAQ:GLYC) rose 2.79%: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP ...KC RegisterTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that it will present positive data from the Phase 2 dose-finding clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related PTSD (AtEase Study).
05/31/16 09:55 AMShare Rating Focus on Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - HNN - Share Rating Focus on Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)HNNPresently, Wall Street analysts have given a consensus stock rating of 1 on shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
05/31/16 06:07 AMTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/28/16 09:57 AMTonix Pharmaceuticals (TNXP) Announces Presentation of Positive TNX-102 SL Phase 2 Data - Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that it will present positive data from the Phase 2 dose-finding clinical study of TNX-102 SL ...
05/27/16 11:02 AMEarnings Review and Stock Rundown for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Wall Street Hints and News - Earnings Review and Stock Rundown for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Tonix Pharmaceuticals Holding Corp.and more »
05/26/16 07:30 AMTonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting - [GlobeNewswire] - NEW YORK, May 26, 2016-- Tonix Pharmaceuticals Holding Corp., which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder, announced that it will present positive ...
05/26/16 07:26 AMInsiders Are Gradually Buying Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Wall Street Hints and News - Insiders Are Gradually Buying Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) have increased their position in the stock by 25.53% over the past 6 months. Insiders now own 3.00% of total outstanding shares. There are both legal and ...and more »
05/26/16 07:26 AMBroker Roundup For Tonix Pharmaceuticals Holding Corp. (TNXP) - Share Trading News - Broker Roundup For Tonix Pharmaceuticals Holding Corp. (TNXP)Share Trading News01/26/2015 – Tonix Pharmaceuticals Holding Corp. had its “neutral” rating reiterated by analysts at Zacks. They now have a USD 10 price target on the stock. The share price of Tonix Pharmaceuticals Holding Corp. (TNXP) was down -0.44% during the last ...and more »
05/23/16 11:20 AMTNXP: Positive Topline Data Reported for TNX-102 SL in AtEase Trial -
05/21/16 12:42 PMOppenheimer Raises Price Target for Tonix Pharmaceuticals Holding Corp. (TNXP) Following Topline Results from ... - Smarter Analyst - Smarter AnalystOppenheimer Raises Price Target for Tonix Pharmaceuticals Holding Corp. (TNXP) Following Topline Results from ...Smarter AnalystWhile shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) keep tumbling following results from the company's Phase 2 clinical study in patients with military-related PTSD, Oppenheimer analyst Carlos Solorzano remains positive, raising his price ...
05/20/16 01:10 PMRevenue Update on Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP) - Trade Calls - Revenue Update on Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)Trade CallsTonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Earnings per share were $-0.74. Analysts had estimated an EPS of $-0.63.
05/20/16 01:10 PMCantor Reiterates Buy on Tonix Pharmaceuticals Holding Corp. (TNXP) Following Phase 2 Clinical Results in PTSD - Smarter Analyst - share market updates (press release)Cantor Reiterates Buy on Tonix Pharmaceuticals Holding Corp. (TNXP) Following Phase 2 Clinical Results in PTSDSmarter AnalystTNXP Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were on a roller-coaster ride today after the drug maker announced data from its Phase 2 trial in Post Traumatic Stress Disorder (PTSD). While the larger arm dosing 2.8mg of TNX-102 ...Upgrades And Downgrades For Tonix Pharmaceuticals Holding Corp. (TNXP)Risers & FallersHC Stocks in Focus: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), Teva Pharmaceutical Industries Ltd (ADR ...share market updates (press release)Stocks Recommendation Update: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) , St. Jude Medical, Inc ...Street UpdatesScibility Media -The Post -Benchmark Monitorall 28 news articles »
05/19/16 12:45 PM3 Biotech Stocks Making Big Moves on Drug Data - Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we ...
05/19/16 12:45 PMTonix Pharmaceuticals Phase 2 trial success for military related PTSD - Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has unveiled positive results from a trial of a potential new drug to treat military related post-traumatic stress disorder (PTSD). The company said it had successfully demonstrated a dose-response ...
05/19/16 08:05 AMCould This Be the Turning Point for Tonix Pharma? -
05/19/16 05:02 AM6:02 am Tonix Pharma announces topline results of the Phase 2 dose-finding clinical study of TNX-102 SL in military-related PTSD -
05/19/16 05:00 AMTonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) - [GlobeNewswire] - Conference Call and Webcast Today at 8:00 a.m. ET Successfully-executed Dose-finding Study Identified 5.6 mg as the Efficacious and Well-tolerated Dose for Registration Studies Plan to Meet with the U.S. ...
05/13/16 06:49 AM6 Stocks Under $10 Making Big Moves Higher -
05/12/16 09:45 AMTNXP: TNX-102 SL Update -
05/12/16 06:02 AMTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/11/16 06:43 AMConsensus Rating Review for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - B.O.D.Y Confidential - Consensus Rating Review for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)B.O.D.Y ConfidentialOne of these bases is following what opinions professional research analysts have on a particular stock. Equity research analysts currently have a consensus rating of 1 on shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP). Sell-side analysts ...and more »
05/10/16 07:02 AMEye Catching Stocks: Synacor, Inc. (NASDAQ:SYNC), Tonix Pharmaceuticals (NASDAQ:TNXP), NTN Buzztime Inc ... - KC Register - Eye Catching Stocks: Synacor, Inc. (NASDAQ:SYNC), Tonix Pharmaceuticals (NASDAQ:TNXP), NTN Buzztime Inc ...KC RegisterSynacor, Inc. (NASDAQ:SYNC) announced it will hold a conference call to discuss financial results for its first quarter 2016 on Tuesday, May 10, 2016, at 5:00 p.m. Eastern Time, following the release of its quarterly financial results. On Friday ...
05/09/16 07:03 AMTonix Pharmaceuticals Holding Corp. (TNXP) Broker Price Targets For The Coming Week - Share Trading News - Tonix Pharmaceuticals Holding Corp. (TNXP) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Tonix Pharmaceuticals Holding Corp. (TNXP). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/09/16 07:01 AMTonix reports 1Q loss -
05/09/16 06:06 AMTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Stat -
About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TNXP
  • CUSIP:
Key Metrics:
  • Previous Close: $2.05
  • 50 Day Moving Average: $2.38
  • 200 Day Moving Average: $3.60
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $38.73M
  • Current Quarter EPS Consensus Estimate: $-2.31 EPS
Additional Links:
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha